Pasar al contenido principal

REPROGRAMACION METABOLICA PARA COMBATIR LA FIBROSIS RENAL

PID2019-104233RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Enhanced fatty acid oxidation through metformin and baicalin as therapy for COVID-19 and associated inflammatory states in lung and kidney

  • Miguel, Verónica
  • Rey-Serra, Carlos
  • Tituaña, Jessica
  • Sirera, Belén
  • Alcalde-Estévez, Elena
  • Herrero, José Ignacio
  • Ranz, Irene
  • Fernández, Laura
  • Castillo, Carolina
  • Sevilla, Lucía
  • Nagai, James
  • Reimer, Katharina C
  • Jansen, Jitske
  • Kramann, Rafael
  • Costa, Ivan G
  • Castro Morera, Ana
  • Sancho, David
  • Rodríguez González-Moro, José Miguel
  • Lamas Peláez, Santiago
Progressive respiratory failure is the primary cause of death in the coronavirus disease 2019 (COVID-19) pandemic. It is the final outcome of the acute respiratory distress syndrome (ARDS), characterized by an initial exacerbated inflammatory response, metabolic derangement and ultimate tissue scarring. A positive balance of cellular energy may result crucial for the recovery of clinical COVID-19. Hence, we asked if two key pathways involved in cellular energy generation, AMP-activated protein kinase (AMPK)/acetyl-CoA carboxylase (ACC) signaling and fatty acid oxidation (FAO) could be beneficial. We tested the drugs metformin (AMPK activator) and baicalin (CPT1A activator) in different experimental models mimicking COVID-19 associated inflammation in lung and kidney. We also studied two different cohorts of COVID-19 patients that had been previously treated with metformin. These drugs ameliorated lung damage in an ARDS animal model, while activation of AMPK/ACC signaling increased mitochondrial function and decreased TGF-β-induced fibrosis, apoptosis and inflammation markers in lung epithelial cells. Similar results were observed with two indole derivatives, IND6 and IND8 with AMPK activating capacity. Consistently, a reduced time of hospitalization and need of intensive care was observed in COVID-19 patients previously exposed to metformin. Baicalin also mitigated the activation of pro-inflammatory bone marrow-derived macrophages (BMDMs) and reduced kidney fibrosis in two animal models of kidney injury, another key target of COVID-19. In human epithelial lung and kidney cells, both drugs improved mitochondrial function and prevented TGF-β-induced renal epithelial cell dedifferentiation. Our results support that favoring cellular energy production through enhanced FAO may prove useful in the prevention of COVID-19-induced lung and renal damage., This work was supported by grants PID2019-104233RB-I00 and PID2022-136703OB-I00 funded by MCIN /AEI/10.13039/501100011033 / FEDER, Spanish National Research Council CSIC–COV19-096/PIE202020E160, Comunidad de Madrid “NOVELREN” B2017/BMD-3751 and Fundación Renal “Íñigo Alvarez de Toledo”, all from Spain. The CBMSO receives institutional support from Fundación “Ramón Areces”. VM and EA hold a Juan de la Cierva-Formación fellowship from the Spanish Ministry of Science and Innovation (FJC2020-043505-I and FJC2021-046602-I, respectively). VM was supported by a Postdoctoral Long-Term Fellowship from the Federation of European Biochemical Societies (FEBS). CR and BS are recipients of a pre-doctoral fellowship of the FPI Program (BES-2016-076735 and PRE-2020-093831, respectively) from the Spanish Research State Agency
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Impact of renal tubular Cpt1a overexpression on the kidney metabolome in the folic acid-induced fibrosis mouse model

  • Cuevas-Delgado, Paula
  • Miguel, Verónica
  • Rupérez, Francisco J.
  • Lamas Peláez, Santiago
  • Barbas, Coral
Background: Chronic kidney disease (CKD) is characterized by the progressive and irreversible deterioration of kidney function and structure with the appearance of renal fibrosis. A significant decrease in mitochondrial metabolism, specifically a reduction in fatty acid oxidation (FAO) in tubular cells, is observed in tubulointerstitial fibrosis, whereas FAO enhancement provides protection. Untargeted metabolomics offers the potential to provide a comprehensive analysis of the renal metabolome in the context of kidney injury. Methodology: Renal tissue from a carnitine palmitoyl transferase 1a (Cpt1a) overexpressing mouse model, which displays enhanced FAO in the renal tubule, subjected to folic acid nephropathy (FAN) was studied through a multiplatform untargeted metabolomics approach based on LC-MS, CE-MS and GC-MS analysis to achieve the highest coverage of the metabolome and lipidome affected by fibrosis. The expression of genes related to the biochemical routes showing significant changes was also evaluated. Results: By combining different tools for signal processing, statistical analysis and feature annotation, we were able to identify variations in 194 metabolites and lipids involved in many metabolic routes: TCA cycle, polyamines, one-carbon metabolism, amino acid metabolism, purine metabolism, FAO, glycerolipids and glycerophospholipids synthesis and degradation, glycosphingolipids interconversion, and sterol metabolism. We found several metabolites strongly altered by FAN, with no reversion induced by Cpt1a overexpression (v.g. citric acid), whereas other metabolites were influenced by CPT1A-induced FAO (v.g. glycine-betaine). Conclusion: It was implemented a successful multiplatform metabolomics approach for renal tissue analysis. Profound metabolic changes accompany CKD-associated fibrosis, some associated with tubular FAO failure. These results highlight the importance of addressing the crosstalk between metabolism and fibrosis when undertaking studies attempting to elucidate the mechanism of CKD progression., his study was supported by the Ministry of Science and Innovation of Spain (MICIN), PID2019-104233RB-100/AEI/10.13039/501100011033 and PID2021-122490NB-I00/AEI/10.13039/501100011033 by ERDF-“A way of making Europe” and the Autonomous Community of Madrid NOVELREN-CM B2017/BMD3751. The CBMSO receives institutional support from Fundación “Ramón Areces”. PC-D is supported by a fellowship from CEU International Doctoral School (CEINDO). And VM was supported by a FEBS Long-Term Fellowship, and by predoctoral fellowships of the Formación de Personal Investigador (FPI) program (BES-2013-065986) from MINECO., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Reciprocal regulation between the molecular clock and kidney injury

  • Rey-Serra, Carlos
  • Tituaña, Jessica
  • Lin, Terry
  • Herrero, José Ignacio
  • Miguel, Verónica
  • Barbas, Coral
  • Meseguer, Anna
  • Ramos, Ricardo
  • Chaix, Amandine
  • Panda, Satchidananda
  • Lamas Peláez, Santiago
Tubulointerstitial fibrosis is the common pathological substrate for many etiologies leading to chronic kidney disease. Although perturbations in the circadian rhythm have been associated with renal disease, the role of the molecular clock in the pathogenesis of fibrosis remains incompletely understood. We investigated the relationship between the molecular clock and renal damage in experimental models of injury and fibrosis (unilateral ureteral obstruction, folic acid, and adenine nephrotoxicity), using genetically modified mice with selective deficiencies of the clock components Bmal1, Clock, and Cry. We found that the molecular clock pathway was enriched in damaged tubular epithelial cells with marked metabolic alterations. In human tubular epithelial cells, TGFβ significantly altered the expression of clock components. Although Clock played a role in the macrophage-mediated inflammatory response, the combined absence of Cry1 and Cry2 was critical for the recruitment of neutrophils, correlating with a worsening of fibrosis and with a major shift in the expression of metabolism-related genes. These results support that renal damage disrupts the kidney peripheral molecular clock, which in turn promotes metabolic derangement linked to inflammatory and fibrotic responses., This work was supported by grants from the Ministerio de Ciencia e Innovación PID2019-104233RB-100/AEI/10.13039/501100011033 (S Lamas), Instituto de Salud Carlos III REDinREN RD12/0021/0009 and RD16/0009/0016 (S Lamas), Comunidad de Madrid “NOVELREN” B2017/BMD-3751 and INNOREN P2022/BMD-7221 (S Lamas and C Barbas), and Fundación Renal “Iñigo Alvarez de Toledo” (S Lamas), all from Spain. C Rey-Serra has been the recipient of an FPI research training contract from the Spanish Research State Agency (BES-2016-076735). The CBMSO receives institutional support from Fundación “Ramón Areces.”, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Antifibrotic Agents for the Management of CKD: A Review

  • Ruiz-Ortega, Marta
  • Lamas Peláez, Santiago
  • Ortiz, Alberto
Kidney fibrosis is a hallmark of chronic kidney disease (CKD) and a potential therapeutic target. However, there are conceptual and practical challenges to directly targeting kidney fibrosis. Whether fibrosis is mainly a cause or a consequence of CKD progression has been disputed. It is unclear whether specifically targeting fibrosis is feasible in clinical practice because most drugs that decrease fibrosis in preclinical models target additional and often multiple pathogenic pathways (eg, renin-angiotensin-aldosterone system blockade). Moreover, tools to assess whole-kidney fibrosis in routine clinical practice are lacking. Pirfenidone, a drug used for idiopathic pulmonary fibrosis, is undergoing a phase 2 trial for kidney fibrosis. Other drugs in use or being tested for idiopathic pulmonary fibrosis (eg, nintedanib, PRM-151, epigallocatechin gallate) are also potential candidates to treat kidney fibrosis. Novel therapeutic approaches may include antagomirs (eg, lademirsen) or drugs targeting interleukin 11 or NKD2 (WNT signaling pathway inhibitor). Reversing the dysfunctional tubular cell metabolism that leads to kidney fibrosis offers additional therapeutic opportunities. However, any future drug targeting fibrosis of the kidneys should demonstrate added benefit to a standard of care that combines renin-angiotensin system with mineralocorticoid receptor (eg, finerenone) blockade or with sodium/glucose cotransporter 2 inhibitors., This work was supported by grants from Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI17/00119, PI20/00140, DTS20/00083, PI18/01366, PI19/00588, PI19/00815, DTS18/00032, Red de Investigacion Renal REDINREN: RD16/0009, RICORS2040 RD21/0005/0001) Comunidad Autonoma de Madrid FEDER-a way to build Europe (B2017/ BMD-3751 NOVELREN-CM to MR-O and SL); Convocatoria Dinamizacion Europa Investigacion 2019 ” MINECO (EIN2019-103294 to M.R-O B2017/BMD-3686 CIFRA2-CM to AO); Innovation programme under the Marie Skłodowska-Curie grant of the European Union’s Horizon 2020 (IMPROVE-PD ID: 812699) to MR-O; and ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071, Sociedad Espanola de Nefrología, FRIAT, Comunidad de Madrid en Biomedicina and Ministerio de Ciencia e Innovación: PID2019-104233RB-I00/AEI/10.13039/501100011033 to SL
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Metabolism and bioenergetics in the pathophysiology of organ fibrosis

  • Miguel, Verónica
  • Alcalde-Estévez, Elena
  • Sirera, Belén
  • Rodríguez-Pascual, Fernando
  • Lamas Peláez, Santiago
Fibrosis is the tissue scarring characterized by excess deposition of extracellular matrix (ECM) proteins, mainly collagens. A fibrotic response can take place in any tissue of the body and is the result of an imbalanced reaction to inflammation and wound healing. Metabolism has emerged as a major driver of fibrotic diseases. While glycolytic shifts appear to be a key metabolic switch in activated stromal ECM-producing cells, several other cell types such as immune cells, whose functions are intricately connected to their metabolic characteristics, form a complex network of pro-fibrotic cellular crosstalk. This review purports to clarify shared and particular cellular responses and mechanisms across organs and etiologies. We discuss the impact of the cell-type specific metabolic reprogramming in fibrotic diseases in both experimental and human pathology settings, providing a rationale for new therapeutic interventions based on metabolism-targeted antifibrotic agents., This work was supported by grants from the Spanish Ministry of Science PID2022-136703OB-I00 and PID2019-104233RB-100/AEI/10.13039/501100011033, Comunidad de Madrid Innoren-CM 2022/BMD-7227 and Fundación Renal “Íñigo Álvarez de Toledo”, all from Spain. The CBMSO receives institutional support from Fundación “Ramón Areces”. VM was supported by a FEBS Long-Term Fellowship. VM and EA hold a Juan de la Cierva-Formación fellowship from the Spanish Ministry of Science and Innovation (FJC2020-043505-I and FJC2021-046602-I, respectively). BS is recipient of a pre-doctoral fellowship of the FPI Program (PRE2020-093831) from the Spanish Research State Agency.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Multiplatform Metabolomic Profiling of the Unilateral Ureteral Obstruction Murine Model of CKD

  • Cuevas-Delgado, Paula
  • Miguel, Verónica
  • Lamas Peláez, Santiago
  • Barbas, Coral
  • Rupérez, Francisco J.
This article belongs to the Topic Animal Models of Human Disease 3.0., The datasets generated (primary MS data) and/or analyzed (feature areas) during the current study will be openly available in the Metabolomics Workbench repository at http://dx.doi.org/10.21228/M87N8N., In chronic kidney disease (CKD) research, animal models such as the unilateral ureteral obstruction (UUO) rodent model are crucial to understanding disease progression, particularly renal fibrosis. Despite its widespread use, the molecular mechanisms driving CKD remain incompletely understood. Given the interplay between metabolism and fibrosis, a comprehensive metabolomic analysis of UUO renal tissue is necessary. This study involved untargeted multiplatform analysis using liquid chromatography (LC), gas chromatography (GC), and capillary electrophoresis (CE) coupled with mass spectrometry (MS) to examine murine kidney tissue from the UUO model. The results highlight metabolic changes associated with tubulointerstitial fibrosis, which affect pathways such as the tricarboxylic acid (TCA) cycle, the urea cycle, and lipid metabolism. In particular, fibrosis impacts the lipidomic profile, with decreases in most lipid classes and increases in specific glycerophospholipids, hexosylceramides, and cholesterol esters. These findings demonstrate the value of a multiplatform approach in elucidating metabolic alterations in CKD, providing information on the underlying molecular mechanisms and paving the way for further research., This study was supported by the Ministry of Science and Innovation of Spain (MICIN), PID2019-104233RB-100/AEI/10.13039/501100011033, PID2021-122490NB-I00/AEI/10.13039/501100011033 by ERDF-”A way of making Europe” and the Autonomous Community of Madrid NOVELREN-CM B2017/BMD3751 and INNOREN-CM S2022/BMD-7221. The CBMSO receives institutional support from Fundación “Ramón Areces”. Cuevas-Delgado P. was supported by a fellowship from CEU International Doctoral School (CEINDO) and Miguel V. was supported by a predoctoral fellowships of the Formación de Personal Investigador (FPI) program (BES-793 2013-065986) from MINECO., Peer reviewed